DUBLIN--(BUSINESS WIRE)--The "Traumatic Brain Injury - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Traumatic Brain Injury - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Traumatic Brain Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Traumatic Brain Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Traumatic Brain Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 7, 10, 63 and 7 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 9 and 1 molecules, respectively.
Traumatic Brain Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
1. Introduction
2. Traumatic Brain Injury - Overview
3. Traumatic Brain Injury - Therapeutics Development
4. Traumatic Brain Injury - Therapeutics Assessment
5. Traumatic Brain Injury - Companies Involved in Therapeutics Development
6. Traumatic Brain Injury - Drug Profiles
7. Traumatic Brain Injury - Dormant Projects
8. Traumatic Brain Injury - Discontinued Products
9. Traumatic Brain Injury - Product Development Milestones
10. Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/wn82kj/traumatic_brain?w=4.
